Data protection Impressum

Oncology

Medtech start-up Novigenix has received EUR 1.8 million from the EU’s Innovative Health Initiative to support the industrialization of its AI-driven liquid biopsy platform as part of a major international cancer research collaboration.

Novigenix secures EUR 1.8 million to scale precision oncology platform

9 April 2025

TheraMe!, a Lausanne-based medtech, is transforming cancer treatment by partnering with CSEM to develop an automated, microfluidic-based instrument. This breakthrough technology enables personalized drug screening on live tumor samples, providing cancer patients with tailored therapy recommendations before treatment begins.

CSEM and TheraMe! transform cancer therapy with personalized drug screening technology

28 January 2025

Limula, Actival, and AirCurve have received funding from the FIT to advance groundbreaking solutions in cell therapy production, dental health, and tracheal intubation. Limula secured a CHF 500,000 Tech Growth loan, while Actival and AirCurve each received CHF 100,000 Tech Seed loans.

Western Switzerland healthcare start-ups Limula, Actival, and AirCurve secure FIT funding

16 December 2024

Lymphatica Medtech, a Lausanne-based clinical-stage company specializing in innovative treatments for lymphedema, has raised EUR 17.9 million in a Series B funding round.

Lymphatica Medtech secures EUR 17.9 million to advance lymphedema treatment

15 October 2024

HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments to advance RNA-guided therapies for obesity and metabolic disorders.

HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery

17 September 2024

BioAlps, the life sciences cluster of Western Switzerland, offers a dynamic network, an innovative and supportive environment and direct access to the region's vibrant life sciences ecosystem.

Why Switzerland

BioAlps, Western Switzerland’s life sciences cluster

iOnctura has secured EUR 80 million in a Series B funding round to advance innovative cancer therapies, with a focus on neglected cancers such as uveal melanoma.

iOnctura secures EUR 80 million Series B financing to advance cancer treatments

25 June 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (May 2024)

28 May 2024

HeroSupport and Calico Biosystems join Tech4Eva, a six-month equity-free accelerator dedicated to advancing women’s health technologies globally.

HeroSupport and Calico Biosystems selected for the Tech4Eva accelerator program

15 May 2024

EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.

Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment

6 May 2024

1 2 3 4 5 … 8